Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By


GSK research aims to unlock P-med sales

GlaxoSmithKline (GSK) has unveiled new research to help pharmacists “unlock behind-the-counter sales".

GSK said the research has revealed opportunities to accelerate the growth of the pharmacy-only section of the market through “optimising the back wall”.

Paul Griffith, senior manager, global shopper insights at GSK, said prescriptions are a “driving factor” for shoppers to visit the pharmacy, which highlights a “key opportunity” to secure unplanned purchases.

“We suggest clear signage and in-store communications to encourage shoppers to speak to the pharmacist about their needs,” Mr Griffith said.

He also recommended merchandising the back wall in a way that mirrors the healthcare aisle. "For example, showing clear sub-categories and featuring seasonal products," Mr Griffith added.

The 'back wall project' is part of GSK’s ‘Pharmacy of the Future’ initiative.

For more information, contact your local GSK sales representative.

Will you order this product?

Related Content


Stamford, Lincolnshire
£50-55,000 per annum

Apply Now
Latest News & Analysis
See All



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts